Viz.ai has announced a partnership with BIOS Clinical Trials Coordinating Center (BIOS CTTC) for accelerating the enrolment of patients in the Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH) clinical trial.
BIOS CTTC is an academic research organisation within the Johns Hopkins School of Medicine Department of Neurology.
Funded by the National Institutes of Health (NIH), the BEACH study has been designed to study the tolerability and safety of MW189, a small molecule developed by the University of Kentucky co-principal investigator (PI) Dr Linda Van Eldik.
MW189 selectively attenuates the overproduction of injury-induced and disease-induced proinflammatory cytokine in ICH patients.
Under this collaboration, BEACH research teams will get access to the Viz RECRUIT software, Viz.ai’s clinical trial acceleration platform.
This platform has demonstrated a 3X² acceleration in clinical trial enrolment and identifies patients eligible for the trial by scanning their images in real time.
This allows for the automatic identification of potential study subjects around-the-clock, and notifications will be sent to research teams.
Viz.ai chief clinical officer Jayme Strauss said: “Clinical trial enrolment is often a bottleneck when it comes to developing novel therapies.
“Viz RECRUIT software is designed to speed up clinical trial enrolment and promote diversity in clinical trials by identifying more eligible participants.”
The platform will automatically identify patients with suspected ICH for the BEACH trial, with the inclusion of volumetric assessment criteria ranging between 10ml and 60ml.
It will also notify members of the research and BIOS CTCC teams of trial subjects through the HIPAA-compliant web-based and phone-based app of Viz.ai that aids in image viewing, communication, and coordination.
Last November, Viz.ai and Vastrax announced a strategic partnership to expedite clinical trial enrolment for research on new neurovascular therapies.